Basket | Login | Register

 
 
 
 

IMI launches final IMI2 Calls for proposals, including Call on neurodegenerative diseases research

Tuesday 23 June 2020

On 23 June 2020, the Innovative Medicines Initiative (IMI) launched the last Calls for proposals under the IMI2 programme. The Calls cover six topic areas, including one on research into neurodegenerative diseases (NDs) such as Alzheimer’s and Parkinson’s diseases. The NDs Call aims to create a platform that will make it possible for researchers to see what samples and data are available and access them for further research. The hope is that by opening up these samples and data, researchers will be able to discover new biomarkers that will ultimately help to diagnose patients, monitor their disease, and select the most appropriate treatment. Other topic areas relate to tackling cancer through artificial intelligence, antimicrobial resistance, rare disease diagnosis, the return of clinical trial data to participants, and patient adherence.

IMI will contribute a total of EUR 59 million to the projects funded under the Calls; these funds come from Horizon 2020 and will support the participation in the projects of organisations such as universities, small and medium-sized enterprises (SMEs), and patient groups. EFPIA companies and IMI Associated Partners will contribute EUR 47 million, mostly as “in kind” contributions. Stage 1 submission deadline is 29 September 2020 (17.00 CET).

Read the full press release, here: https://www.imi.europa.eu/news-events/press-releases/imi-launches-final-imi2-calls-proposals

The information about call topics and how to submit proposals can be found here: https://www.imi.europa.eu/apply-funding/open-calls/imi2-call-23

Options